Please assess the completion status of the following clinical trial:

Trial Title: Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of breast cancer~  * T2-T4c, any N, M0 disease~* Clinically staged, as documented by the treating physician, as 1 of the following:~  * T4a-c disease for which modified radical mastectomy with negative margins is the goal~ * T2 or T3 disease for which conversion from needing mastectomy to breast conservation is the goal~ * T2 disease for which lumpectomy at first attempt is the goal~* Primary tumor must be palpable and measure \> 2 cm by tape, ruler, or caliper measurements in at least one dimension~* Must agree to undergo mastectomy or lumpectomy after neoadjuvant aromatase inhibitor therapy~* No inflammatory breast cancer, defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema)~* No distant metastasis (M1)~  * Isolated ipsilateral supraclavicular node involvement allowed~* No diagnosis that was established by incisional biopsy~* Must have estrogen receptor (ER) positive tumor with an Allred score of 6, 7 or 8~  * Patients with \> 66.66% (two-thirds) of cells staining positive and have a minimum Allred score of 6 are eligible~PATIENT CHARACTERISTICS:~* ECOG/Zubrod performance status of ≤ 2~* Female~* Patient must be postmenopausal, verified by 1 of the following:~  * Bilateral surgical oophorectomy~ * No spontaneous menses ≥ 1 year~ * No menses for \< 1 year with FSH and estradiol levels in postmenopausal range~* No other malignancies within the past 5 years, except for successfully treated cervical carcinoma in situ; lobular carcinoma in situ of the breast; contralateral ductal carcinoma in situ that was treated with mastectomy or lumpectomy with radiotherapy (without tamoxifen); or non-melanoma skin cancer with no evidence of recurrence~  * Must have undergone potentially curative therapy for all prior malignancies AND deemed to be at low risk for recurrence, according to the treating physician~PRIOR CONCURRENT THERAPY:~* No prior treatment for invasive breast cancer, including radiotherapy, endocrine therapy, chemotherapy, or investigational agents~* No prior sentinel lymph node biopsy (cohort B only)~* At least 1 week since prior agents with estrogenic or putatively estrogenic properties, including herbal preparations~* At least 1 week since prior hormone replacement therapy of any type, megestrol acetate, or raloxifene~* No concurrent enrollment in another neoadjuvant clinical trial for treatment of the existing breast cancer~* No other concurrent anti-neoplastic therapy, including chemotherapy or radiotherapy~* No concurrent agents or herbal products that alter ER function

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral exemestane once daily for up to 16-18 weeks.
- Arm II (Type: EXPERIMENTAL): Patients receive oral letrozole once daily for up to 16-18 weeks.
- Arm III (Type: EXPERIMENTAL): Patients receive oral anastrozole once daily for up to 16-18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).